Key Takeaways & Executive Findings
- •• Pharmaceutical care in China is hospital-centric, with limited community integration, hindering continuity of care. • Key barriers include workforce shortages, non-standardized protocols, and insufficient interprofessional collaboration. • Implementation of pharmaceutical care significantly improves medication adherence, reduces adverse drug events, and boosts patient satisfaction. • Policy reforms and digital health tools are critical to scaling pharmaceutical care across China's diverse healthcare settings.
Abstract
Pharmaceutical care has evolved globally as a patient-centered practice, yet its implementation in China faces unique challenges. This systematic review synthesizes evidence from 2010 to 2024 to evaluate the current status, barriers, and outcomes of pharmaceutical care in Chinese healthcare settings. A comprehensive search of PubMed, CNKI, and Wanfang databases identified 1,245 articles, of which 38 met inclusion criteria. Findings reveal that pharmaceutical care in China is predominantly hospital-based, focusing on medication reconciliation, therapeutic drug monitoring, and patient education. However, significant barriers include workforce shortages, lack of standardized protocols, and limited integration with primary care. Despite these challenges, studies demonstrate improved medication adherence, reduced adverse drug events, and enhanced patient satisfaction. The review proposes a framework for advancing pharmaceutical care through policy reforms, interprofessional collaboration, and digital health technologies. Future directions emphasize community-based services and personalized medicine to align with global standards.
1. Introduction
Pharmaceutical care, defined as the responsible provision of drug therapy to achieve definite outcomes that improve a patient's quality of life, has become a cornerstone of modern healthcare. Globally, the shift from product-oriented to patient-oriented practice has enhanced medication safety and therapeutic outcomes. In China, the healthcare system has undergone rapid reforms, yet the integration of pharmaceutical care remains inconsistent, particularly in primary care and community settings.
This systematic review aims to critically evaluate the current state of pharmaceutical care in China, identifying successful models, persistent barriers, and opportunities for advancement. By synthesizing evidence from diverse studies, we provide a comprehensive overview that informs policymakers, practitioners, and researchers. The findings underscore the urgent need for standardized frameworks and innovative strategies to align Chinese practice with international benchmarks.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, H. Li, J. Chen (2026). Pharmaceutical Care in China: A Systematic Review of Current Status and Future Directions. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_242
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the current state of pharmaceutical care in China?
Pharmaceutical care in China is predominantly hospital-based, focusing on medication reconciliation, therapeutic drug monitoring, and patient education. However, community integration is limited, and services are often fragmented.
What are the main barriers to implementing pharmaceutical care in China?
Key barriers include workforce shortages, lack of standardized protocols, limited interprofessional collaboration, and insufficient integration with primary care and community settings.
Does pharmaceutical care improve patient outcomes in China?
Yes, studies show that pharmaceutical care significantly improves medication adherence, reduces adverse drug events, and enhances patient satisfaction, leading to better therapeutic outcomes.
What future directions are recommended for pharmaceutical care in China?
Future directions include policy reforms to support community-based services, interprofessional education, and the adoption of digital health technologies to enable personalized medicine and continuity of care.
How does pharmaceutical care in China compare to global standards?
While China has made progress, it lags in community-based and patient-centered approaches compared to countries like the US and UK. Standardization and integration are needed to align with international benchmarks.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.